Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Average Recommendation of “Hold” from Brokerages

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) has received a consensus recommendation of “Hold” from the eight ratings firms that are currently covering the stock, Marketbeat reports. Seven equities research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company.

A number of research analysts recently issued reports on BAYRY shares. Berenberg Bank lowered shares of Bayer Aktiengesellschaft from a “buy” rating to a “hold” rating in a research note on Wednesday, August 16th. Deutsche Bank Aktiengesellschaft lowered shares of Bayer Aktiengesellschaft from a “buy” rating to a “hold” rating in a research note on Tuesday, November 14th. HSBC raised shares of Bayer Aktiengesellschaft from a “reduce” rating to a “hold” rating in a report on Tuesday, October 10th. They noted that the move was a valuation call. Finally, Redburn Atlantic downgraded shares of Bayer Aktiengesellschaft from an “overweight” rating to a “neutral” rating in a report on Monday, September 25th.

Bayer Aktiengesellschaft Stock Performance

Shares of BAYRY opened at $9.31 on Thursday. Bayer Aktiengesellschaft has a 12 month low of $9.13 and a 12 month high of $17.00. The company’s fifty day moving average is $11.57 and its 200-day moving average is $13.23. The company has a quick ratio of 0.78, a current ratio of 1.20 and a debt-to-equity ratio of 0.98. The firm has a market cap of $36.59 billion, a price-to-earnings ratio of -9.04, a price-to-earnings-growth ratio of 0.12 and a beta of 1.23.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its earnings results on Wednesday, November 8th. The company reported $0.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.10). Bayer Aktiengesellschaft had a negative net margin of 7.98% and a positive return on equity of 14.76%. The firm had revenue of $11.26 billion during the quarter, compared to analyst estimates of $12.62 billion. Equities analysts expect that Bayer Aktiengesellschaft will post 1.69 EPS for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy.